Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5FBN

BTK kinase domain with inhibitor 1

Summary for 5FBN
Entry DOI10.2210/pdb5fbn/pdb
DescriptorTyrosine-protein kinase BTK, 4-[8-azanyl-3-[(3~{R})-1-(3-methyloxetan-3-yl)carbonylpiperidin-3-yl]imidazo[1,5-a]pyrazin-1-yl]-~{N}-[4-(trifluoromethyl)pyridin-2-yl]benzamide, 4-[8-azanyl-3-[(2~{S})-1-[4-(dimethylamino)butanoyl]pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-~{N}-(1,3-thiazol-2-yl)benzamide, ... (6 entities in total)
Functional Keywordskinase, phosphatase, transferase-transferase inhibitor complex, transferase
Biological sourceHomo sapiens (Human)
Total number of polymer chains2
Total formula weight66563.23
Authors
Raaijmakers, H.C.A.,Vu-Pham, D. (deposition date: 2015-12-14, release date: 2016-02-03, Last modification date: 2024-05-01)
Primary citationLiu, J.,Guiadeen, D.,Krikorian, A.,Gao, X.,Wang, J.,Boga, S.B.,Alhassan, A.B.,Yu, Y.,Vaccaro, H.,Liu, S.,Yang, C.,Wu, H.,Cooper, A.,de Man, J.,Kaptein, A.,Maloney, K.,Hornak, V.,Gao, Y.D.,Fischmann, T.O.,Raaijmakers, H.,Vu-Pham, D.,Presland, J.,Mansueto, M.,Xu, Z.,Leccese, E.,Zhang-Hoover, J.,Knemeyer, I.,Garlisi, C.G.,Bays, N.,Stivers, P.,Brandish, P.E.,Hicks, A.,Kim, R.,Kozlowski, J.A.
Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis.
Acs Med.Chem.Lett., 7:198-203, 2016
Cited by
PubMed Abstract: Bruton's tyrosine kinase (BTK) is a Tec family kinase with a well-defined role in the B cell receptor (BCR) pathway. It has become an attractive kinase target for selective B cell inhibition and for the treatment of B cell related diseases. We report a series of compounds based on 8-amino-imidazo[1,5-a]pyrazine that are potent reversible BTK inhibitors with excellent kinase selectivity. Selectivity is achieved through specific interactions of the ligand with the kinase hinge and driven by aminopyridine hydrogen bondings with Ser538 and Asp539, and by hydrophobic interaction of trifluoropyridine in the back pocket. These interactions are evident in the X-ray crystal structure of the lead compounds 1 and 3 in the complex with the BTK enzyme. Our lead compounds show desirable PK profiles and efficacy in the preclinical rat collagen induced arthritis model.
PubMed: 26985298
DOI: 10.1021/acsmedchemlett.5b00463
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.8 Å)
Structure validation

246704

PDB entries from 2025-12-24

PDB statisticsPDBj update infoContact PDBjnumon